Serial no. | Age | Sex | Clinical Response | % Reduction in Parasitaemia | Route of Administration I.M/P.O | Serum Lipid Profile Change | |||||||||
TG | T.Chol | HDL-C | LDL-C | VLDL-C | |||||||||||
Abs Change (mmol/L) | % Change | Abs Change (mmol/L) | % Change | Abs Change (mmol/L) | % Change | Abs Change (mmol/L) | % Change | Abs Change (mmol/L) | % Change | ||||||
1 | 39 | F | 2+ | 86% | IM | +0.1 | 8% | +0.3 | 9% | −0.1 | 11% | +1.8 | 95% | −0.1 | 17% |
2 | 3 | M | 1+ | 50% | PO | +0.5 | 45% | +1.6 | 59% | 0 | 0% | +1.4 | 93% | +0.2 | 40% |
3 | 38 | M | 2+ | 60% | IM | +0.7 | 54% | −0 | 0% | −0.3 | 25% | 0 | 0% | +0.3 | 50% |
4 | 25 | M | 0 | 9% | IM | +0.3 | 30% | +0.2 | 4% | −0.5 | 38% | +0.6 | 19% | +0.1 | 20% |
5 | 44 | F | 1+ | 58% | IM | −0.1 | 8% | +0.3 | 6% | −0.3 | 27% | +0.7 | 23% | −0.1 | 17% |
6 | 3 | M | 1+ | 52% | PO | +0.3 | 23% | +0.1 | 3% | −0.3 | 30% | +0.3 | 17% | +0.1 | 17% |
7 | 44 | M | 1+ | 60% | IM | +0.5 | 36% | +0.8 | 15% | 0 | 0% | +0.5 | 14% | +0.3 | 50% |
8 | 38 | M | 2+ | 82% | IM | +0.4 | 40% | −0.5 | 11% | +0.1 | 10% | −0.7 | 22% | +0.1 | 20% |
9 | 14 | F | 1+ | 57% | PO | +0.1 | 9% | −0.6 | 16% | +0.1 | 14% | −0.7 | 28% | 0 | 0% |
10 | 22 | F | 2+ | 86% | IM | +0.5 | 28% | −0.9 | 15% | −0.2 | 14% | −0.9 | 24% | +0.2 | 25% |
11 | 15 | F | 1+ | 50% | IM | −0.4 | 24% | −0.2 | 5% | +0.2 | 20% | −0.2 | 8% | −0.2 | 25% |
12 | 22 | F | 2+ | 60% | IM | +0.1 | 6% | −0.3 | 5% | +0.1 | 8% | −0.5 | 14% | +0.1 | 13% |
13 | 30 | F | 0 | 20% | PO | +0.8 | 89% | −0.4 | 8% | +0.1 | 8% | −0.9 | 25% | +0.4 | 100% |
14 | 38 | M | 1+ | 50% | IM | −0.3 | 17% | +0.2 | 5% | +0.2 | 17% | +0.1 | 5% | −0.1 | 13% |
15 | 40 | F | 0 | 33% | IM | +0.3 | 21% | −0.3 | 6% | +0.3 | 30% | −0.8 | 26% | +0.2 | 33% |
16 | 25 | F | 2+ | 82% | IM | −0.3 | 20% | +0.8 | 19% | −0.1 | 10% | +1.1 | 44% | −0.2 | 29% |
17 | 25 | F | 2+ | 60% | PO | −1.4 | 58% | −1.3 | 26% | −0.2 | 17% | −0.5 | 19% | −0.6 | 55% |
18 | 30 | F | 2+ | 84% | PO | +0.1 | 6% | +2.1 | 42% | −0.2 | 10% | +2.2 | 100% | +0.1 | 13% |
19 | 57 | M | 2+ | 60% | IM | −1.3 | 57% | −1.4 | 22% | −0.5 | 33% | −0.4 | 10% | −0.5 | 50% |
20 | 26 | F | 0 | −24% | PO | −0.7 | 41% | −0.6 | 12% | −1.3 | 59% | +1 | 50% | −0.3 | 38% |
21 | 19 | F | 1+ | 45% | PO | +1 | 111% | −0.4 | 8% | +0.1 | 8% | −1 | 28% | +0.5 | 125% |
22 | 20 | M | 0 | −11% | IM | +0.4 | 25% | +0.9 | 24% | −0.4 | 33% | +1.1 | 61% | +0.2 | 29% |
23 | 4 | M | 1+ | −50% | IM | +0.5 | 56% | +1.3 | 35% | +0.2 | 20% | +0.9 | 39% | +0.2 | 50% |
24 | 22 | F | 2+ | 86% | PO | −0.2 | 15% | +0.2 | 5% | 0 | 0% | +0.3 | 12% | −0.1 | 17% |
25 | 30 | F | 1+ | 57% | IM | +0.3 | 38% | −0.4 | 8% | 0 | 0% | −0.5 | 14% | +0.1 | 25% |
26 | 27 | M | 2+ | 60% | PO | −0.2 | 13% | −0.8 | 15% | −0.1 | 10% | −0.6 | 16% | −0.1 | 14% |
27 | 35 | F | 2+ | 78% | IM | +0.1 | 10% | +0.5 | 14% | −0.1 | 10% | +0.6 | 27% | 0 | 0% |
28 | 22 | M | 2+ | 80% | IM | +0.2 | 18% | −0.4 | 9% | −0.1 | 9% | −0.4 | 14% | +0.1 | 20% |
29 | 22 | F | 2+ | 82% | PO | +0.2 | 15% | −0.5 | 10% | +0.1 | 9% | −0.7 | 23% | +0.1 | 17% |
30 | 30 | M | 2+ | 60% | PO | −1.5 | 52% | −0.5 | 10% | −0.6 | 38% | +0.8 | 42% | −0.7 | 54% |